Dr. Ravandi on Relapse/Refractory AML
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapse/refractory acute myeloid leukemia (AML).
Farhad Ravandi, MD, professor, Department of Leukemia, Division of Cancer Medicine, chief, Section of Developmental Therapeutics, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapse/refractory acute myeloid leukemia (AML).
Ravandi says the outcomes for patients with this disease are currently poor. Studies have looked at the population of cells in these patients, and there are certain complexities, such as clonal evolution and clonal selection, which make patients less amenable to traditional cytotoxins.
Ravandi believes that the treatment paradigm will move away from giving patients high doses of cytotoxins, with the exception of those who have a very long first remission duration. He adds that he and his colleagues will incorporate novel agents, in order to discover better strategies.
In order to prevent relapse/refractory AML, monitoring minimal residual disease, as well as eradicating it, becomes significant, concludes Ravandi.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases
December 29th 2024In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.
Read More
